These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 31250747)

  • 1. Multifunctional Ligands Targeting Phosphodiesterase as the Future Strategy for the Symptomatic and Disease-Modifying Treatment of Alzheimer's Disease.
    Jankowska A; Wesołowska A; Pawłowski M; Chłoń-Rzepa G
    Curr Med Chem; 2020; 27(32):5351-5373. PubMed ID: 31250747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-Target-Directed Ligands Affecting Serotonergic Neurotransmission for Alzheimer's Disease Therapy: Advances in Chemical and Biological Research.
    Jankowska A; Wesolowska A; Pawlowski M; Chlon-Rzepa G
    Curr Med Chem; 2018; 25(17):2045-2067. PubMed ID: 28554324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diabetic Theory in Anti-Alzheimer's Drug Research and Development - Part 1: Therapeutic Potential of Antidiabetic Agents.
    Jankowska A; Wesołowska A; Pawłowski M; Chłoń-Rzepa G
    Curr Med Chem; 2020; 27(39):6658-6681. PubMed ID: 31604406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multifunctional Ligands with Glycogen Synthase Kinase 3 Inhibitory Activity as a New Direction in Drug Research for Alzheimer's Disease.
    Jankowska A; Satała G; Bojarski AJ; Pawłowski M; Chłoń-Rzepa G
    Curr Med Chem; 2021; 28(9):1731-1745. PubMed ID: 32338201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic Strategies Targeting Amyloid-β in Alzheimer's Disease.
    Pinheiro L; Faustino C
    Curr Alzheimer Res; 2019; 16(5):418-452. PubMed ID: 30907320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting New Pharmacological Approaches for Alzheimer's Disease: Potential for Statins and Phosphodiesterase Inhibitors.
    Sallustio F; Studer V
    CNS Neurol Disord Drug Targets; 2016; 15(6):647-59. PubMed ID: 27189469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diabetic Theory in Anti-Alzheimer's Drug Research and Development. Part 2: Therapeutic Potential of cAMP-Specific Phosphodiesterase Inhibitors.
    Jankowska A; Pawłowski M; Chłoń-Rzepa G
    Curr Med Chem; 2021; 28(18):3535-3553. PubMed ID: 32940168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of phosphodiesterase: A novel therapeutic target for the treatment of mild cognitive impairment and Alzheimer's disease.
    Sheng J; Zhang S; Wu L; Kumar G; Liao Y; Gk P; Fan H
    Front Aging Neurosci; 2022; 14():1019187. PubMed ID: 36268188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer's disease.
    Prickaerts J; Heckman PRA; Blokland A
    Expert Opin Investig Drugs; 2017 Sep; 26(9):1033-1048. PubMed ID: 28772081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tea polyphenols as multi-target therapeutics for Alzheimer's disease: An in silico study.
    Mazumder MK; Choudhury S
    Med Hypotheses; 2019 Apr; 125():94-99. PubMed ID: 30902161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural products against Alzheimer's disease: Pharmaco-therapeutics and biotechnological interventions.
    Dey A; Bhattacharya R; Mukherjee A; Pandey DK
    Biotechnol Adv; 2017; 35(2):178-216. PubMed ID: 28043897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reducing Aβ load and tau phosphorylation: Emerging perspective for treating Alzheimer's disease.
    Kalra J; Khan A
    Eur J Pharmacol; 2015 Oct; 764():571-581. PubMed ID: 26209363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphodiesterase inhibitors as a target for cognition enhancement in aging and Alzheimer's disease: a translational overview.
    Heckman PR; Wouters C; Prickaerts J
    Curr Pharm Des; 2015; 21(3):317-31. PubMed ID: 25159073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphodiesterase inhibitors say NO to Alzheimer's disease.
    Nabavi SM; Talarek S; Listos J; Nabavi SF; Devi KP; Roberto de Oliveira M; Tewari D; Argüelles S; Mehrzadi S; Hosseinzadeh A; D'onofrio G; Orhan IE; Sureda A; Xu S; Momtaz S; Farzaei MH
    Food Chem Toxicol; 2019 Dec; 134():110822. PubMed ID: 31536753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. From Age-Related Cognitive Decline to Alzheimer's Disease: A Translational Overview of the Potential Role for Phosphodiesterases.
    Heckman PRA; Blokland A; Prickaerts J
    Adv Neurobiol; 2017; 17():135-168. PubMed ID: 28956332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Phosphodiesterase Inhibitors for Cognitive Improvement in Alzheimer's Disease.
    Wu Y; Li Z; Huang YY; Wu D; Luo HB
    J Med Chem; 2018 Jul; 61(13):5467-5483. PubMed ID: 29363967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Herbs to curb cyclic nucleotide phosphodiesterase and their potential role in Alzheimer's disease.
    Kumar A; Sharma V; Singh VP; Kaundal M; Gupta MK; Bariwal J; Deshmukh R
    Mech Ageing Dev; 2015 Jul; 149():75-87. PubMed ID: 26050556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphodiesterase (PDE) III inhibitor, Cilostazol, improved memory impairment in aluminum chloride-treated rats: modulation of cAMP/CREB pathway.
    Khalifa M; Abdelsalam RM; Safar MM; Zaki HF
    Inflammopharmacology; 2022 Dec; 30(6):2477-2488. PubMed ID: 35727381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synaptic dysfunction in Alzheimer's disease: Mechanisms and therapeutic strategies.
    Chen Y; Fu AKY; Ip NY
    Pharmacol Ther; 2019 Mar; 195():186-198. PubMed ID: 30439458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.